The fact that this Akt inhibitor mediates cell death in a similar way as Sorafenib, even in resistant cells like the 786-O line, provides strong support for the use of new PI3K/Akt/mTOR inhibitors in the treatment of RCC (for a review see [67]). The gene discussed is MTOR; the disease is renal cell carcinoma.